Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | VP of Finance and Controller | November 20, 2024 | November 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date November 20, 2024 · Filed November 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,854 |
Reported balance
After 2024-11-20 transaction · row 1
1 source rowRow 1 · 2024-11-20 · Grant · Acquired 25,000 · Balance 118,854 F1: This reflects restricted stock units ("RSUs") that will vest in full on November 20, 2025, subject to the reporting person's continued services to the Issuer through the vesting date. The RSUs will be settled in stock within 30 days after each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that will vest in full on November 20, 2025, subject to the reporting person's continued services to the Issuer through the vesting date. The RSUs will be settled in stock within 30 days after each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2024 Filed Nov 22, 2024 21:01 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001871155-24-000005 · wk-form4_1732309285.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,854 F1 · shares: This reflects restricted stock units ("RSUs") that will vest in full on November 20, 2025, subject to the reporting person's continued services to the Issuer through the vesting date. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:13 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,839 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001619856-22-000003 · wf-form4_166517721515147.xml · derivative · entry 5 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,337 Underlying: Common Stock · 2,839 shares Expires 2031-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:13 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 2,839 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001619856-22-000003 · wf-form4_166517721515147.xml · derivative · entry 4 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,704 Underlying: Common Stock · 2,839 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to this option vested on January 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:13 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 2,839 | $4.11 | $11,668.29 |
DisclosureSEC source: 0001619856-22-000003 · wf-form4_166517721515147.xml · nonDerivative · entry 3 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 4,848 shares represented by restricted stock units ("RSUs") that vest in two equal annual installments beginning on August 22, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:13 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 2,839 | $2.69 | $7,636.91 |
DisclosureSEC source: 0001619856-22-000003 · wf-form4_166517721515147.xml · nonDerivative · entry 2 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 4,848 shares represented by restricted stock units ("RSUs") that vest in two equal annual installments beginning on August 22, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:13 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 10,000 | $10.80 | $107,958.00 |
DisclosureSEC source: 0001619856-22-000003 · wf-form4_166517721515147.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,366 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.67 to $10.94, inclusive. The reporting person undertakes to provide to Caribou Biosciences, Inc., any security holder of Caribou Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 4,848 shares represented by restricted stock units ("RSUs") that vest in two equal annual installments beginning on August 22, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 21:25 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 4,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047368 · doc4.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,366 F1 · shares: Represents a grant of restricted stock units ("RSUs") that vest in two equal annual installments beginning on August 22, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:28 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 1,138 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-22-027696 · doc4.xml · derivative · entry 4 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,176 Underlying: Common Stock · 1,138 shares Expires 2031-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. The vesting schedule for this option was inadvertently described incorrectly in the reporting person's Form 3 filed on July 23, 2021. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:28 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 1,136 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-027696 · doc4.xml · derivative · entry 3 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,543 Underlying: Common Stock · 1,136 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. F2 · derivative.exercise_date: 1/4th of the shares subject to this option vested on January 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter so that the option is fully vested on January 1, 2023, subject to the reporting person's continues service to the Issuer through the applicable vesting dates. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:28 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 1,138 | $4.11 | $4,677.18 |
DisclosureSEC source: 0001209191-22-027696 · doc4.xml · nonDerivative · entry 2 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:28 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 1,136 | $2.69 | $3,055.84 |
DisclosureSEC source: 0001209191-22-027696 · doc4.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 23:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 1,138 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-22-019808 · doc4.xml · derivative · entry 4 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,314 Underlying: Common Stock · 1,138 shares Expires 2031-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 23:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 1,136 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-019808 · doc4.xml · derivative · entry 3 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,679 Underlying: Common Stock · 1,136 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. F3 · derivative.exercise_date: 1/4th of the shares subject to this option vested on January 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. The vesting schedule for this option was inadvertently described incorrectly in the reporting person's Form 3 filed on July 23, 2021. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 23:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 1,138 | $4.11 | $4,677.18 |
DisclosureSEC source: 0001209191-22-019808 · doc4.xml · nonDerivative · entry 2 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 23:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 1,136 | $2.69 | $3,055.84 |
DisclosureSEC source: 0001209191-22-019808 · doc4.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. F2 · balance_after: Includes 1,888 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2022 for $9.85 per share. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:35 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 6,818 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-22-003062 · doc4.xml · derivative · entry 4 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,452 Underlying: Common Stock · 6,818 shares Expires 2031-03-29 F4 · derivative.exercise_date: 1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:35 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 569 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-22-003062 · doc4.xml · derivative · entry 3 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,815 Underlying: Common Stock · 569 shares Expires 2029-03-18 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. F3 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:35 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 6,818 | $4.11 | $28,021.98 |
DisclosureSEC source: 0001209191-22-003062 · doc4.xml · nonDerivative · entry 2 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,082 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:35 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 569 | $2.69 | $1,530.61 |
DisclosureSEC source: 0001209191-22-003062 · doc4.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,264 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:23 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 40,000 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001209191-21-070797 · doc4.xml · derivative · entry 3 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-12-19 F4 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on December 20, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:23 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 1,136 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-21-070797 · doc4.xml · derivative · entry 2 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,384 Underlying: Common Stock · 1,136 shares Expires 2029-03-18 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. F3 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:23 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 1,136 | $2.69 | $3,055.84 |
DisclosureSEC source: 0001209191-21-070797 · doc4.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,695 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. F2 · price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 23:33 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | OtherOption to purchase Common Stock · Derivative | 1,746 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001209191-21-060289 · doc4.xml · derivative · entry 2 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,520 Underlying: Common Stock · 1,746 shares Expires 2029-03-18 F2 · derivative.exercise_price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. F3 · derivative.exercise_date: The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 23:33 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 1,746 | $2.69 | $4,696.74 |
DisclosureSEC source: 0001209191-21-060289 · doc4.xml · nonDerivative · entry 1 Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,559 F1 · kind: These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below. F2 · price: The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.